QLINE — Q-Line Biotech Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual income statement for Q-Line Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	PROSPECTUS	PROSPECTUS	PROSPECTUS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	6,084	3,655	4,073	6,276	—
Cost of Revenue
Gross Profit	1,579	943	1,106	1,681	—
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	4,619	3,003	3,381	5,245	2,739
Operating Profit	1,465	652	692	1,031	—
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,426	597	612	884	—
Provision for Income Taxes
Net Income After Taxes	1,100	428	433	490	—
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	1,100	642	689	563	—
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,100	642	689	563	—
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	47.2	27.5	29.3	32.2	—